Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.30 |
| ▸ | PRKACG | P22612 | 1/20 | 0.30 |
| ▸ | PRKACB | P22694 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964814 | 0.92 | MAPK1 (0.50) | MAPK1MTORCNR1KCNH2MAPKAPK2 | |
| SCHEMBL29964534 | 0.91 | MAPK1 (0.44) | MAPK1CD274KLKB1KCNH2MAPKAPK2 | |
| SCHEMBL31079295 | 0.91 | MAPK1 (0.45) | MAPK1CD274KLKB1KCNH2MAPKAPK2 | |
| SCHEMBL29914811 | 0.90 | MAPK1 (0.39) | MAPK1MTORCD274CNR1KCNH2 | |
| SCHEMBL31079301 | 0.88 | MTOR (0.37) | MAPK1MTORCD274MAPKAPK2GABRG2 | |
| SCHEMBL29964709 | 0.86 | MAPK1 (0.42) | MAPK1MTORCD274KCNH2MAPKAPK2 | |
| SCHEMBL27159793 | 0.84 | MAPK1 (0.46) | MAPK1MTORCNR1KCNH2MAPKAPK2 | |
| SCHEMBL31079180 | 0.84 | MAPK1 (0.40) | MAPK1CD274KLKB1CNR1KCNH2 | |
| SCHEMBL31079189 | 0.83 | MAPK1 (0.43) | MAPK1KCNH2 | |
| SCHEMBL29964214 | 0.82 | MAPK1 (0.53) | MAPK1KCNH2MAPKAPK2GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | MAPK1 141/4885MTOR 642/4885CD274 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.